PMC:7463108 / 100234-105195 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T19 304-313 Body_part denotes G protein http://purl.org/sig/ont/fma/fma61788
T20 382-386 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T21 622-626 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T22 639-642 Body_part denotes CNS http://purl.org/sig/ont/fma/fma55675
T23 729-733 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T24 1320-1323 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T25 1510-1513 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T26 2650-2660 Body_part denotes astrocytes http://purl.org/sig/ont/fma/fma54537
T27 2990-2993 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T28 3018-3027 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T29 3045-3055 Body_part denotes chemokines http://purl.org/sig/ont/fma/fma241981
T30 3237-3245 Body_part denotes monocyte http://purl.org/sig/ont/fma/fma62864
T31 3904-3908 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T32 4015-4025 Body_part denotes G proteins http://purl.org/sig/ont/fma/fma61788
T33 4189-4199 Body_part denotes G proteins http://purl.org/sig/ont/fma/fma61788
T34 4301-4304 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T35 4425-4428 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T36 4455-4464 Body_part denotes microglia http://purl.org/sig/ont/fma/fma68923
T37 4769-4778 Body_part denotes G protein http://purl.org/sig/ont/fma/fma61788

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T189 639-642 Body_part denotes CNS http://purl.obolibrary.org/obo/UBERON_0001017

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T16 148-156 http://purl.obolibrary.org/obo/CLO_0001658 denotes activate
T17 188-195 http://purl.obolibrary.org/obo/SO_0000418 denotes signals
T18 314-323 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T19 382-386 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T20 489-497 http://purl.obolibrary.org/obo/PR_000018263 denotes peptides
T21 594-595 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T22 622-631 http://purl.obolibrary.org/obo/CL_0000000 denotes cell type
T23 639-642 http://www.ebi.ac.uk/efo/EFO_0000302 denotes CNS
T24 639-642 http://www.ebi.ac.uk/efo/EFO_0000908 denotes CNS
T25 729-738 http://purl.obolibrary.org/obo/CL_0000000 denotes cell-type
T26 1088-1095 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T27 2000-2001 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T28 2039-2040 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T29 2108-2112 http://purl.obolibrary.org/obo/CLO_0001185 denotes 2018
T30 2157-2160 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T31 2650-2660 http://purl.obolibrary.org/obo/CL_0000127 denotes astrocytes
T32 3237-3245 http://purl.obolibrary.org/obo/CL_0000576 denotes monocyte
T33 3404-3405 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T34 3605-3614 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T35 3886-3896 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T36 3904-3913 http://purl.obolibrary.org/obo/CL_0000000 denotes cell type
T37 3932-3933 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T38 3952-3961 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T39 4001-4011 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T40 4129-4141 http://purl.obolibrary.org/obo/OBI_0000245 denotes organization
T41 4150-4159 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T42 4215-4218 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T43 4276-4280 http://purl.obolibrary.org/obo/CLO_0001185 denotes 2018
T44 4309-4312 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T45 4455-4464 http://purl.obolibrary.org/obo/CL_0000129 denotes microglia

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T14873 105-113 Chemical denotes morphine http://purl.obolibrary.org/obo/CHEBI_17303|http://purl.obolibrary.org/obo/CHEBI_58097
T68259 115-124 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T91935 130-143 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T40 306-313 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T10193 353-361 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T91421 489-497 Chemical denotes peptides http://purl.obolibrary.org/obo/CHEBI_16670
T47036 976-984 Chemical denotes morphine http://purl.obolibrary.org/obo/CHEBI_17303|http://purl.obolibrary.org/obo/CHEBI_58097
T92077 986-995 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T1111 999-1012 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T51088 1442-1446 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T76461 1587-1591 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T96964 1989-1998 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T55392 2011-2018 Chemical denotes agonist http://purl.obolibrary.org/obo/CHEBI_48705
T75231 2024-2037 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T1452 2053-2060 Chemical denotes agonist http://purl.obolibrary.org/obo/CHEBI_48705
T55931 2073-2083 Chemical denotes antagonist http://purl.obolibrary.org/obo/CHEBI_48706
T54595 2132-2141 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T51815 2143-2156 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T42352 2662-2669 Chemical denotes agonist http://purl.obolibrary.org/obo/CHEBI_48705
T52338 2831-2839 Chemical denotes morphine http://purl.obolibrary.org/obo/CHEBI_17303|http://purl.obolibrary.org/obo/CHEBI_58097
T42965 2841-2850 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T60 2856-2869 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T67960 2894-2897 Chemical denotes ROS http://purl.obolibrary.org/obo/CHEBI_26523
T65348 2969-2977 Chemical denotes Morphine http://purl.obolibrary.org/obo/CHEBI_17303
T94219 3142-3151 Chemical denotes methadone http://purl.obolibrary.org/obo/CHEBI_6807
T10937 3153-3162 Chemical denotes oxycodone http://purl.obolibrary.org/obo/CHEBI_7852
T56838 3164-3177 Chemical denotes buprenorphine http://purl.obolibrary.org/obo/CHEBI_3216
T19929 3183-3188 Chemical denotes DAMGO http://purl.obolibrary.org/obo/CHEBI_272
T33804 3370-3375 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T55394 3575-3583 Chemical denotes agonists http://purl.obolibrary.org/obo/CHEBI_48705
T93088 3771-3779 Chemical denotes agonists http://purl.obolibrary.org/obo/CHEBI_48705
T83042 4017-4025 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T71 4191-4199 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T52460 4343-4351 Chemical denotes agonists http://purl.obolibrary.org/obo/CHEBI_48705
T13815 4383-4388 Chemical denotes DAMGO http://purl.obolibrary.org/obo/CHEBI_272
T81707 4392-4400 Chemical denotes morphine http://purl.obolibrary.org/obo/CHEBI_17303|http://purl.obolibrary.org/obo/CHEBI_58097
T39669 4650-4657 Chemical denotes agonist http://purl.obolibrary.org/obo/CHEBI_48705
T86579 4735-4742 Chemical denotes ligands http://purl.obolibrary.org/obo/CHEBI_52214
T61999 4771-4778 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3464 157-160 Gene denotes MOR Gene:4988
3465 204-207 Gene denotes MOR Gene:4988
3466 263-265 Gene denotes Gα Gene:8802
3467 893-896 Gene denotes MOR Gene:4988
3468 325-328 Gene denotes RGS Gene:5308
3469 1320-1323 Species denotes HIV Tax:12721
3470 105-113 Chemical denotes morphine MESH:D009020
3471 115-124 Chemical denotes methadone MESH:D008691
3472 130-143 Chemical denotes buprenorphine MESH:D002047
3473 976-984 Chemical denotes morphine MESH:D009020
3474 986-995 Chemical denotes methadone MESH:D008691
3475 999-1012 Chemical denotes buprenorphine MESH:D002047
3507 2087-2090 Gene denotes KOR Gene:4986
3508 2310-2313 Gene denotes MOR Gene:4988
3509 2370-2373 Gene denotes MOR Gene:4988
3510 2691-2694 Gene denotes MOR Gene:4988
3511 2699-2702 Gene denotes KOR Gene:4986
3512 2929-2932 Gene denotes Tat Gene:6898
3513 2002-2005 Gene denotes MOR Gene:4988
3514 2041-2044 Gene denotes MOR Gene:4988
3515 3093-3097 Gene denotes Hage Gene:55510
3516 3060-3064 Gene denotes Hage Gene:55510
3517 2990-2995 Species denotes HIV-1 Tax:11676
3518 1510-1513 Species denotes HIV Tax:12721
3519 1989-1998 Chemical denotes methadone MESH:D008691
3520 2024-2037 Chemical denotes buprenorphine MESH:D002047
3521 2132-2141 Chemical denotes methadone MESH:D008691
3522 2143-2156 Chemical denotes buprenorphine MESH:D002047
3523 2831-2839 Chemical denotes morphine MESH:D009020
3524 2841-2850 Chemical denotes methadone MESH:D008691
3525 2856-2869 Chemical denotes buprenorphine MESH:D002047
3526 2894-2897 Chemical denotes ROS
3527 2903-2907 Chemical denotes Ca2+ MESH:D000069285
3528 2969-2977 Chemical denotes Morphine MESH:D009020
3529 3142-3151 Chemical denotes methadone MESH:D008691
3530 3153-3162 Chemical denotes oxycodone MESH:D010098
3531 3164-3177 Chemical denotes buprenorphine MESH:D002047
3532 1600-1609 Disease denotes mortality MESH:D003643
3533 1648-1663 Disease denotes opioid overdose MESH:D062787
3534 2220-2224 Disease denotes ARVs
3535 2241-2267 Disease denotes opioid withdrawal symptoms MESH:D013375
3536 2488-2498 Disease denotes neurotoxic MESH:D020258
3544 3399-3402 Gene denotes MOR Gene:4988
3545 3690-3693 Gene denotes MOR Gene:4988
3546 3697-3699 Gene denotes Gα Gene:8802
3547 3767-3770 Gene denotes MOR Gene:4988
3548 3882-3885 Gene denotes MOR Gene:4988
3549 4045-4053 Disease denotes Williams MESH:D018980
3558 4339-4342 Gene denotes MOR Gene:4988
3559 4685-4688 Gene denotes MOR Gene:4988
3560 4811-4823 Gene denotes β-arrestin 2 Gene:409
3561 4425-4430 Species denotes HIV-1 Tax:11676
3562 4301-4304 Species denotes HIV Tax:12721
3563 4360-4373 Chemical denotes endomorphin-1 MESH:C105293
3564 4392-4400 Chemical denotes morphine MESH:D009020
3565 4446-4454 Disease denotes infected MESH:D007239

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T10 83-95 http://purl.obolibrary.org/obo/GO_0009405 denotes Pathogenesis
T11 314-323 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T12 1796-1802 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T13 1796-1802 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T14 1807-1816 http://purl.obolibrary.org/obo/GO_0051235 denotes retention
T15 3605-3614 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T16 3952-3970 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathways
T17 3952-3961 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T18 4150-4159 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T19 4593-4608 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1266 0-95 Sentence denotes Opioid Substitution Therapies and the Role of Selective/Biased Agonism in neuroHIV Pathogenesis
T1267 96-397 Sentence denotes Although morphine, methadone, and buprenorphine all activate MOR, each can impart different signals through MOR, related to the nature and timing of their coupling to Gα, Gβγ, β-arrestin and/or regulators of G protein signaling (RGS), since each downstream effector couples into unique cell functions.
T1268 398-539 Sentence denotes Functional selectivity occurs at each opioid receptor type, and for most endogenous opioid peptides at all three receptor types (Gomes et al.
T1269 540-546 Sentence denotes 2020).
T1270 547-771 Sentence denotes Moreover, opioid receptors can be expressed on a subset of virtually every cell type in the CNS—with second messenger coupling to each opioid receptor type potentially being unique, cell-type specific, and context dependent.
T1271 772-861 Sentence denotes Thus, the “pluridimensional” (Galandrin and Bouvier 2006; Kenakin 2011; Costa-Neto et al.
T1272 862-1096 Sentence denotes 2016) actions of any opiate at MOR are sufficiently complicated that it is not possible to predict whether, e.g., morphine, methadone or buprenorphine, would similarly effect any aspect of neuroHIV pathology without empirical testing.
T1273 1097-1338 Sentence denotes Despite their significant use as medication-assisted therapies for treating opioid addiction, few studies have directly compared commonly used opiate substitution therapies (Bell and Strang 2020), especially in relation to HIV (Khalsa et al.
T1274 1339-1356 Sentence denotes 2006; Choi et al.
T1275 1357-1363 Sentence denotes 2020).
T1276 1364-1493 Sentence denotes Opioid substitution therapies significantly reduce the frequency of injection drug use (Kwiatkowski and Booth 2001; Pettes et al.
T1277 1494-1549 Sentence denotes 2010), decrease HIV transmission risk (MacArthur et al.
T1278 1550-1568 Sentence denotes 2012; Platt et al.
T1279 1569-1625 Sentence denotes 2016), and reduce drug-related mortality (Mathers et al.
T1280 1626-1678 Sentence denotes 2013) and the risk of opioid overdose (Volkow et al.
T1281 1679-1685 Sentence denotes 2014).
T1282 1686-1886 Sentence denotes Further, improved ARV outcomes among PWH have been reported with opioid substitution therapies, including the uptake and retention on ARV, medication adherence rates, and viral suppression (Low et al.
T1283 1887-1911 Sentence denotes 2016; Mukandavire et al.
T1284 1912-1918 Sentence denotes 2017).
T1285 1919-2114 Sentence denotes The two main medications used for opioid substitution therapy include methadone, a MOR full agonist, and buprenorphine, a MOR partial agonist and partial antagonist of KOR (Noble and Marie 2018).
T1286 2115-2395 Sentence denotes In comparison to methadone, buprenorphine has been shown to have fewer pharmacodynamic interactions with ARVs and causes less opioid withdrawal symptoms potentially due to its partial agonism on MOR, but also due to its high affinity and long duration of MOR binding (Walsh et al.
T1287 2396-2445 Sentence denotes 1994; McCance-Katz 2005; Whelan and Remski 2012).
T1288 2446-2567 Sentence denotes Further, differential proinflammatory and neurotoxic effects have been noted for various opioid treatments (Boland et al.
T1289 2568-2588 Sentence denotes 2014; Fitting et al.
T1290 2589-2611 Sentence denotes 2014b; Carvallo et al.
T1291 2612-2638 Sentence denotes 2015; Dutta and Roy 2015).
T1292 2639-2743 Sentence denotes In primary astrocytes, agonist-selective actions at MOR and KOR can be clearly demonstrated (Bohn et al.
T1293 2744-2765 Sentence denotes 2000; Belcheva et al.
T1294 2766-2787 Sentence denotes 2003; McLennan et al.
T1295 2788-2805 Sentence denotes 2008; Hahn et al.
T1296 2806-2960 Sentence denotes 2010), and we found that morphine, methadone, and buprenorphine differentially increase ROS and [Ca2+]i alone or following Tat co-exposure (Fitting et al.
T1297 2961-2968 Sentence denotes 2014b).
T1298 2969-3071 Sentence denotes Morphine can enhance HIV-1-induced production of cytokines and specifically chemokines (El-Hage et al.
T1299 3072-3104 Sentence denotes 2008a; Dave 2012; El-Hage et al.
T1300 3105-3270 Sentence denotes 2014), while other opioids including methadone, oxycodone, buprenorphine, and DAMGO can decrease inflammatory function and decrease monocyte migration (Boland et al.
T1301 3271-3292 Sentence denotes 2014; Carvallo et al.
T1302 3293-3325 Sentence denotes 2015; Jaureguiberry-Bravo et al.
T1303 3326-3347 Sentence denotes 2016; Chilunda et al.
T1304 3348-3354 Sentence denotes 2019).
T1305 3355-3657 Sentence denotes As most opiate drugs preferentially act via MOR, a potential explanation for differential interactive effects of opioids in the context of neuroHIV is the phenomenon of selective or “biased agonism”, such that different agonists can trigger distinct signaling events at the same receptor (Hauser et al.
T1306 3658-3664 Sentence denotes 2012).
T1307 3665-3806 Sentence denotes For example, coupling of MOR to Gα, Gβγ, and/or β-arrestin have been noted to differ depending on the MOR agonists involved (McPherson et al.
T1308 3807-3828 Sentence denotes 2010; Thompson et al.
T1309 3829-3850 Sentence denotes 2015; Burgueno et al.
T1310 3851-3857 Sentence denotes 2017).
T1311 3858-4060 Sentence denotes Physiologic outcomes of MOR activation in any cell type are determined by a bias for specific signaling pathways, the initial step of which is activation of G proteins and/or β-arrestin (Williams et al.
T1312 4061-4081 Sentence denotes 2013b; Violin et al.
T1313 4082-4105 Sentence denotes 2014; Suomivuori et al.
T1314 4106-4112 Sentence denotes 2020).
T1315 4113-4282 Sentence denotes The subcellular organization of GPCR signaling transduced by heterotrimeric G proteins and β-arrestin has been recently reviewed in detail (Eichel and von Zastrow 2018).
T1316 4283-4481 Sentence denotes In the context of HIV, it has been shown that selective MOR agonists such as endomorphin-1, but not DAMGO or morphine, significantly increase HIV-1 replication in infected microglia (Peterson et al.
T1317 4482-4488 Sentence denotes 1999).
T1318 4489-4706 Sentence denotes This effect might be due to an apparent bias of endomorphin-1 towards arrestin recruitment and receptor phosphorylation, which was significantly correlated with agonist-induced internalization of MOR (McPherson et al.
T1319 4707-4713 Sentence denotes 2010).
T1320 4714-4954 Sentence denotes It is suggested that ligands that display bias towards G protein-mediated pathways and away from β-arrestin 2 recruitment may have improved therapeutic profiles against the development of tolerance and dependence/addiction (McPherson et al.
T1321 4955-4961 Sentence denotes 2010).

2_test

Id Subject Object Predicate Lexical cue
32876803-21030484-62958344 838-842 21030484 denotes 2011
32876803-27638872-62958345 862-866 27638872 denotes 2016
32876803-31420089-62958346 1287-1291 31420089 denotes 2020
32876803-17109302-62958347 1339-1343 17109302 denotes 2006
32876803-11391170-62958348 1474-1478 11391170 denotes 2001
32876803-23038795-62958349 1550-1554 23038795 denotes 2012
32876803-23554523-62958350 1626-1630 23554523 denotes 2013
32876803-24758595-62958351 1679-1683 24758595 denotes 2014
32876803-27343545-62958352 1887-1891 27343545 denotes 2016
32876803-28323752-62958353 1912-1916 28323752 denotes 2017
32876803-30713510-62958354 2108-2112 30713510 denotes 2018
32876803-8181201-62958355 2396-2400 8181201 denotes 1994
32876803-16265622-62958356 2415-2419 16265622 denotes 2005
32876803-22346191-62958357 2439-2443 22346191 denotes 2012
32876803-24644198-62958358 2568-2572 24644198 denotes 2014
32876803-25716997-62958359 2612-2616 25716997 denotes 2015
32876803-19895666-62958360 2806-2810 19895666 denotes 2010
32876803-22066570-62958361 3084-3088 22066570 denotes 2012
32876803-24732776-62958362 3105-3109 24732776 denotes 2014
32876803-24644198-62958363 3271-3275 24644198 denotes 2014
32876803-25716997-62958364 3293-3297 25716997 denotes 2015
32876803-27009099-62958365 3326-3330 27009099 denotes 2016
32876803-31473221-62958366 3348-3352 31473221 denotes 2019
32876803-22591368-62958367 3658-3662 22591368 denotes 2012
32876803-20647394-62958368 3807-3811 20647394 denotes 2010
32876803-24460711-62958369 3829-3833 24460711 denotes 2015
32876803-24878326-62958370 4082-4086 24878326 denotes 2014
32876803-32079767-62958371 4106-4110 32079767 denotes 2020
32876803-29478570-62958372 4276-4280 29478570 denotes 2018
32876803-10218868-62958373 4482-4486 10218868 denotes 1999
32876803-20647394-62958374 4707-4711 20647394 denotes 2010
32876803-20647394-62958375 4955-4959 20647394 denotes 2010